HPMC and Myristic Acid Blend for Adiponectin Elevation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological treatments for increasing adiponectin levels are ineffective and often come with negative side effects, failing to address cardiovascular disease and obesity effectively.
Innovation Solution
A composition comprising Hydroxypropyl Methyl Cellulose (HPMC) and anti-inflammatory myristic fatty acid is used to safely and effectively increase plasma adiponectin levels, reducing the risk of cardiovascular disease and body fat.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current pharmacological treatments are used to increase adiponectin levels, then adiponectin levels may be elevated, but the treatments have negative side effects and are ineffective
Solution Approach 1:
The patent changes the chemical composition parameters by using a specific blend of HPMC (Hydroxypropyl Methyl Cellulose) with different molecular weights (K15, K100, K200) and incorporating myristic fatty acid at optimized concentrations (0.1-10% w/w), thereby achieving effective adiponectin elevation without the harmful side effects of conventional pharmacological treatments
Solution Approach 2:
The patent creates a composite pharmaceutical composition combining HPMC polymers with myristic fatty acid, where the synergistic interaction between these components enables effective adiponectin increase while maintaining safety profile, avoiding the harmful effects of single-agent pharmacological interventions
2Quantity of substance
If current pharmacological treatments are used to increase adiponectin levels, then adiponectin levels may be elevated, but the treatments are ineffective at burning fat
Solution Approach 1:
The patent optimizes the molecular weight distribution parameters of HPMC (using K15, K100, K200 grades) and the concentration of myristic fatty acid to achieve a formulation that simultaneously elevates adiponectin and enhances fat metabolism, resolving the ineffectiveness of conventional treatments at burning fat
Solution Approach 2:
The composite formulation of HPMC and myristic fatty acid creates synergistic effects where HPMC provides the structural framework for adiponectin elevation while myristic fatty acid contributes to lipolysis and fat burning, achieving both adiponectin increase and fat metabolism improvement
3Quantity of substance
If HPMC and myristic fatty acid composition is used to increase adiponectin, then adiponectin levels and fat reduction are achieved, but the formulation complexity increases
Solution Approach 1:
The patent segments the HPMC component into three specific molecular weight fractions (K15, K100, K200) with defined proportions, and separates the myristic fatty acid component at optimized concentrations, allowing systematic control and simplification of the formulation process while maintaining efficacy
Solution Approach 2:
The patent establishes specific parameter ranges for HPMC molecular weights (K15: 15,000-30,000, K100: 100,000-200,000, K200: 200,000-400,000) and myristic fatty acid concentration (0.1-10% w/w), transforming the complex formulation into a standardized protocol with controllable parameters
Data Source
AI summary
The invention provides methods for reducing the percentage of body fat, increasing the level of adiponectin, and/or treating or reducing the risk of cardiovascular disease (CVD) and coronary heart disease (CHD). Such methods include administering to an animal or human sufficient levels of a compound comprising a tri blend of HPMC (K15, K100, and K200) and myristic fatty acid.